Overview
- Legal name
- AMPLIFIDX INC
- Registered location
- NEWARK, CA, USA
- Website
- Company website ↗
- Primary NAICS
- 541714 — Research and Development in Biotechnology (except Nanobiotechnology)
- Latest award activity
- Sep 10, 2024
Read company summary
AMPLIFIDX INC is associated with UEI XAAGYAVXZM43 and CAGE 8RJZ6 in public federal records. AcornBids currently links 1 prime award totaling $400.0K in obligations to this entity. Its largest recorded federal customer by obligations is Department of Health and Human Services. Its recorded federal awards include work classified as In-Vitro Diagnostic Substance Manufacturing. These categories describe the loaded award records, not a complete list of company capabilities. Its primary SAM.gov NAICS is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)). Its public SAM.gov registration lists NEWARK, CA, USA.
At a glance
Prime contract obligations across loaded award records. Obligations are not revenue or contract ceilings. Summary updated Oct 5, 2026. Refresh pending; these totals may be out of date.
Business information
Public SAM.gov registration details.
- Legal name
- AMPLIFIDX INC
- UEI
- XAAGYAVXZM43
- CAGE
- 8RJZ6
- Registered address
- 39655 EUREKA DR, NEWARK, CA, 94560, USA
- Registration status
- Active
- Primary NAICS
- 541714 — Research and Development in Biotechnology (except Nanobiotechnology)
- SAM activation
- Sep 16, 2025
- Initial registration
- Oct 8, 2020
- Entity start
- Aug 27, 2020
- SAM updated
- Sep 16, 2025
- Registration expires
- Sep 9, 2026
- Fiscal year end
- Dec 31
- Place of incorporation
- DE, USA
Research brief
Source facts
- Loaded prime-award records link 1 awards and $400,000 in reported obligations to this legal entity. Source
- Recorded awards include In-Vitro Diagnostic Substance Manufacturing (NAICS 325413); this classification is not proof of every company capability. Source
- An example award describes: PHS 2022-1 TOPIC 440 - CANCER PREVENTION & DIAGNOSIS TECHNOLOGIES FOR LOW-RESOURCE SETTINGS Source
Federal award analysis
Net transaction obligations by federal fiscal period.
Reported transaction obligations by federal fiscal period; includes deobligations. Missing transactions are not estimated. Coverage: 1 of 1 selected awards. Select a period to explore its awards.
Funding change
Dated, valued transaction obligations in equal-length adjacent periods; missing records are unknown. Default: last completed federal fiscal year. Percentage is unavailable when the prior period has no positive reported obligations.
| Measure | Reported value |
|---|---|
| Current period | Oct 1, 2025 – Sep 30, 2026 |
| Current obligations | Not reported |
| Prior period | Oct 1, 2024 – Sep 30, 2025 |
| Prior obligations | Not reported |
| Change | Not reported |
| Growth | Not comparable |
Where the work is performed
State tile map; darker tiles have larger absolute net obligations. Outlined tiles indicate net deobligations. Unshaded tiles have no reported transactions in this selection. Other locations appear in the table.
Agencies
| Category | Period obligations | Awards |
|---|---|---|
| Department of Health and Human Services | $400.0K | 1 |
Offices
| Category | Period obligations | Awards |
|---|---|---|
| NIH NCI | $400.0K | 1 |
Naics
| Category | Period obligations | Awards |
|---|---|---|
| 325413 — In-Vitro Diagnostic Substance Manufacturing | $400.0K | 1 |
Psc
| Category | Period obligations | Awards |
|---|---|---|
| AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH | $400.0K | 1 |
Vehicles
| Category | Period obligations | Awards |
|---|---|---|
| Unclassified | $400.0K | 1 |
States
| Category | Period obligations | Awards |
|---|---|---|
| CA | $400.0K | 1 |
Set Asides
| Category | Period obligations | Awards |
|---|---|---|
| SMALL BUSINESS SET ASIDE - TOTAL | $400.0K | 1 |
Recent federal awards
Prime contract awards. Select an award to review its history and source evidence.
| Award / description | Awarding agency | Obligations | Start date | End date |
|---|---|---|---|---|
| 75N91022C00060PHS 2022-1 TOPIC 440 - CANCER PREVENTION & DIAGNOSIS TECHNOLOGIES FOR LOW-RESOURCE SETTINGS | Department of Health and Human Services | $400.0K | Sep 16, 2022 | Jun 15, 2025 |
Registration, certifications & contacts
| Registration evidence | Date |
|---|---|
| SAM updated | Sep 16, 2025 |
| Source loaded | Sep 26, 2026 |
| Initial registration | Oct 8, 2020 |
| Entity start | Aug 27, 2020 |
Registration classifications: Self Certified Small Disadvantaged Business, Woman Owned Small Business, Woman Owned Business, Small Business. These are separate from the reported certificates above.
| Industry | Reported size status |
|---|---|
| 325413 — In-Vitro Diagnostic Substance Manufacturing | Not reported |
| 541714 — Research and Development in Biotechnology (except Nanobiotechnology) | Not reported |
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| NANCY SCHOENBRUNNER | Government business | Contact method not published | SAM registration | Not available |
| NANCY SCHOENBRUNNER | Electronic business | Contact method not published | SAM registration | Not available |
Registered industries
- 325413 — In-Vitro Diagnostic Substance Manufacturing
- 541714 — Research and Development in Biotechnology (except Nanobiotechnology)
Registration classifications and published certificates do not by themselves establish eligibility for a particular solicitation. View SAM source
Related companies worth researching
Explore the customer, work and award-size evidence behind each match.
Data coverage and methodology
Sources: SAM.gov registration, USAspending awards and transactions, and linked supporting records. Prime contract obligations, IDV ceilings and assistance amounts are kept separate. Missing records are not zero activity. Company claims are labeled separately. Recompete signals are rule-based scores out of 100. Positioning windows are AcornBids estimates.
Disclosed relationships only. Missing records do not establish that a contractor has no partners. Ambiguous parent award identifiers are excluded.
Recently viewed companies
Keep your research moving
Save this company, track changes, and evaluate upcoming work against your targets.
Save to my research Find my fit